JP2012516686A - Ｃｆｔｒを発現する細胞株およびそれらを使用する方法 - Google Patents

Ｃｆｔｒを発現する細胞株およびそれらを使用する方法 Download PDF

Info

Publication number
JP2012516686A
JP2012516686A JP2011548377A JP2011548377A JP2012516686A JP 2012516686 A JP2012516686 A JP 2012516686A JP 2011548377 A JP2011548377 A JP 2011548377A JP 2011548377 A JP2011548377 A JP 2011548377A JP 2012516686 A JP2012516686 A JP 2012516686A
Authority
JP
Japan
Prior art keywords
cftr
cell
cells
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011548377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012516686A5 (enExample
Inventor
シェクダール，カンビーズ
ランガー，ジェシカ
ベンカタチャラン，スリニバサン，ピー．
ソーチャック，デニス，ジェイ．
Original Assignee
クロモセル コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クロモセル コーポレーション filed Critical クロモセル コーポレーション
Publication of JP2012516686A publication Critical patent/JP2012516686A/ja
Publication of JP2012516686A5 publication Critical patent/JP2012516686A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/03—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
    • C12Y306/03049—Channel-conductance-controlling ATPase (3.6.3.49)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/382—Cystic fibrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2011548377A 2009-02-02 2010-02-01 Ｃｆｔｒを発現する細胞株およびそれらを使用する方法 Pending JP2012516686A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14931209P 2009-02-02 2009-02-02
US61/149,312 2009-02-02
PCT/US2010/022778 WO2010088630A2 (en) 2009-02-02 2010-02-01 Cell lines expressing cftr and methods of using them

Publications (2)

Publication Number Publication Date
JP2012516686A true JP2012516686A (ja) 2012-07-26
JP2012516686A5 JP2012516686A5 (enExample) 2013-03-21

Family

ID=42396394

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011548377A Pending JP2012516686A (ja) 2009-02-02 2010-02-01 Ｃｆｔｒを発現する細胞株およびそれらを使用する方法

Country Status (6)

Country Link
US (2) US20120058918A1 (enExample)
EP (1) EP2393930A4 (enExample)
JP (1) JP2012516686A (enExample)
CA (1) CA2751215A1 (enExample)
MX (1) MX2011008131A (enExample)
WO (1) WO2010088630A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016505254A (ja) * 2012-12-12 2016-02-25 ルサッフル・エ・コンパニーＬｅｓａｆｆｒｅ Ｅｔ Ｃｏｍｐａｇｎｉｅ 下痢を治療および／または予防するプロバイオティクス株

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2245046B1 (en) * 2008-01-22 2019-09-04 Chromocell Corporation Novel cell lines expressing nav and methods using them
CA2713885A1 (en) * 2008-02-01 2009-08-20 Chromocell Corporation Novel cell lines and methods
WO2011014740A2 (en) 2009-07-31 2011-02-03 Chromocell Corporation Methods and composition for identifying and validating modulators of cell fate
WO2012162468A1 (en) * 2011-05-25 2012-11-29 Janssen Pharmaceutica Nv Thiazol derivatives as pro -matrix metalloproteinase inhibitors
US20130014288A1 (en) * 2011-06-06 2013-01-10 Carnegie Mellon University Novel reporter-tagged recombinant membrane proteins with transmembrane linkers
WO2017196843A1 (en) * 2016-05-09 2017-11-16 Proteostasis Therapeutics, Inc. Methods of identifying cftr modulators
US11723579B2 (en) 2017-09-19 2023-08-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11478603B2 (en) 2017-12-31 2022-10-25 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
WO2020056418A1 (en) 2018-09-14 2020-03-19 Neuroenhancement Lab, LLC System and method of improving sleep
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
CN111910008B (zh) * 2020-08-21 2022-05-31 云南农业大学 一种鸡生长发育相关的分子标记及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001003722A1 (en) * 1999-07-09 2001-01-18 Mayo Foundation For Medical Education And Research Cftr polypeptides, fragments thereof and methods of use to overcome biosynthetic misprocessing

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164782A1 (en) * 1999-02-10 2002-11-07 Gregory Richard J. Adenovirus vectors for gene therapy
WO2004020596A2 (en) * 2002-08-30 2004-03-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Polypeptides for increasing mutant cftr channel activity
AU2005251745A1 (en) * 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
WO2006101740A2 (en) * 2005-03-18 2006-09-28 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr processing and uses thereof
CA2602793C (en) * 2005-04-13 2016-11-22 Astrazeneca Ab A host cell comprising a vector for production of proteins requiring gamma-carboxylation
MX2008014437A (es) * 2006-05-19 2008-11-27 Scripps Research Inst Tratamiento de desplegamiento de proteinas.
WO2008121199A2 (en) * 2007-03-28 2008-10-09 University Of Iowa Research Foundation Transgenic animal models of disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001003722A1 (en) * 1999-07-09 2001-01-18 Mayo Foundation For Medical Education And Research Cftr polypeptides, fragments thereof and methods of use to overcome biosynthetic misprocessing

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016505254A (ja) * 2012-12-12 2016-02-25 ルサッフル・エ・コンパニーＬｅｓａｆｆｒｅ Ｅｔ Ｃｏｍｐａｇｎｉｅ 下痢を治療および／または予防するプロバイオティクス株

Also Published As

Publication number Publication date
EP2393930A4 (en) 2012-08-15
MX2011008131A (es) 2012-01-20
CA2751215A1 (en) 2010-08-05
EP2393930A2 (en) 2011-12-14
US20120058918A1 (en) 2012-03-08
WO2010088630A3 (en) 2010-11-25
US20150315554A1 (en) 2015-11-05
WO2010088630A2 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
JP2012516686A (ja) Ｃｆｔｒを発現する細胞株およびそれらを使用する方法
CN101960014B (zh) 细胞系以及制备和使用其的方法
EP2391647B1 (en) Cell lines expressing nav and methods of using them
KR101751074B1 (ko) 신규한 세포주와 방법
US8097422B2 (en) Kir channel modulators
EP2622351B1 (en) Neuropeptide q as modulator of gpcr galr2 and uses thereof
EP2245046B1 (en) Novel cell lines expressing nav and methods using them
JP4324474B2 (ja) Ｇタンパク質共役受容体媒介活性の新規細胞系アッセイ
Sato et al. Skeletal muscle ryanodine receptor mutations associated with malignant hyperthermia showed enhanced intensity and sensitivity to triggering drugs when expressed in human embryonic kidney cells
Wang et al. Functional evaluation of a novel GRIN2B missense variant associated with epilepsy and intellectual disability
US20120028278A1 (en) Cell lines expressing guanylate cyclase-c and methods of using them
EP2483696B1 (en) Natural peptide and derivatives as modulators of GPCR GPR1 and uses thereof
HK1152321B (en) Cell lines expressing gabaa and methods of using them
CN1986783A (zh) 表达hERG的稳定细胞系
HK1167875A (en) Novel cell lines and methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140926

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141003

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150324